VETOQUINOL SA (VETO.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:VETO - FR0004186856 - Common Stock
VETO.PA Key Statistics, Chart & Performance
The current stock price of VETO.PA is 73.3 EUR. In the past month the price decreased by -7.54%. In the past year, price decreased by -8.83%.
VETO.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.36 | 209.67B | ||
| SAN.PA | SANOFI | 11.28 | 208.31B | ||
| SNW.DE | SANOFI | 11.28 | 208.31B | ||
| MRK.DE | MERCK KGAA | 13.6 | 50.43B | ||
| UCB.BR | UCB SA | 37.46 | 46.78B | ||
| UNC.DE | UCB SA | 37.17 | 46.41B | ||
| 1BAYN.MI | BAYER AG-REG | 5.75 | 30.17B | ||
| BAYN.DE | BAYER AG-REG | 5.71 | 29.95B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.84 | 10.64B | ||
| IPN.PA | IPSEN | 12.1 | 10.42B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 100.96 | 9.35B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 18.41 | 7.90B |
Related stock screener links
About VETO.PA
Company Profile
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte and currently employs 2,497 full-time employees. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
Company Info
VETOQUINOL SA
Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex
Lure BOURGOGNE-FRANCHE-COMTE FR
Employees: 2519
Phone: 33384625555
VETOQUINOL SA / VETO.PA FAQ
What does VETO do?
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte and currently employs 2,497 full-time employees. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
What is the stock price of VETOQUINOL SA today?
The current stock price of VETO.PA is 73.3 EUR. The price increased by 1.38% in the last trading session.
Does VETOQUINOL SA pay dividends?
VETOQUINOL SA (VETO.PA) has a dividend yield of 1.23%. The yearly dividend amount is currently 0.85.
What is the ChartMill technical and fundamental rating of VETO stock?
VETO.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for VETOQUINOL SA?
VETOQUINOL SA (VETO.PA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the number of employees for VETOQUINOL SA?
VETOQUINOL SA (VETO.PA) currently has 2519 employees.
Can you provide the market cap for VETOQUINOL SA?
VETOQUINOL SA (VETO.PA) has a market capitalization of 870.80M EUR. This makes VETO.PA a Small Cap stock.
VETO.PA Technical Analysis
VETO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VETO.PA. VETO.PA has an excellent financial health rating, but there are some minor concerns on its profitability.
VETO.PA Financial Highlights
Over the last trailing twelve months VETO.PA reported a non-GAAP Earnings per Share(EPS) of 5.1. The EPS increased by 27.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.26% | ||
| ROA | 8.26% | ||
| ROE | 10.57% | ||
| Debt/Equity | 0.02 |
VETO.PA Forecast & Estimates
11 analysts have analysed VETO.PA and the average price target is 92.57 EUR. This implies a price increase of 26.28% is expected in the next year compared to the current price of 73.3.
For the next year, analysts expect an EPS growth of 0.46% and a revenue growth -1.84% for VETO.PA